

Drug Discovery Tools to Examine Neuroinflammation Signalling in Human iPSC-Derived Microglia

Emma V. Jones¹*, Lorna M. FitzPatrick¹*, Mairi Challinor¹, Eve Corrie¹, Rebecca Kelly¹, Dominic Simpson², Lucy Frost¹ and Emily Offer¹ ¹Medicines Discovery Catapult, Block 35, Alderley Park, Cheshire, SK10 4ZF, UK. (*equal contribution) ²James & Lillian Martin Centre for Stem Cell Research, Sir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK

md.catapult.org.uk


• Huge challenges exist in central nervous system (CNS) drug discovery: There is significant unmet need across the spectrum of CNS disorders.

• There has been renewed interest in developing novel CNS therapeutics and innovation with advances in human iPSC cell models, biomarker research and understanding immune system contribution.


• Neuroinflammation is proposed to play a major role in across the spectrum of CNS disorders, including neurodegenerative diseases such as Alzheimer's and Parkinson's.


• Microglia, the resident immune cells of the CNS, are key mediators of neuroinflammation in the CNS. Recently, recently there has been a significant effort directed towards developing human in vitro iPSC-microglia cell models, with the aim to improve the understanding of disease mechanisms and to increase clinical translation.

- At MDC, we have generated functional iPSC-microglia that respond to inflammatory stimuli.
- We have established lentiviral based reporters to interrogate inflammation signalling and inflammasome activation for drug discovery projects.
- Together these represent invaluable drug discovery tools for investigating CNS and inflammatory diseases.




3. Molecular Profiling of MDC iPSC-Microglia Demonstrates they are Responsive to Inflammatory and Disease-causing Stimuli






A53T (10µg/ml) (24 hours) using the Nanostring nCounter Neuroinflammation panel (770 genes) **B)** Graphs showing differences in mRNA levels in selected genes involved in cytokine/chemokine signalling and inflammation pathways upon treatment with stimuli. C) Table displaying the number of differentially expressed genes (DEGs) in MDC iPSCmicroglia arising with the different treatments

4. Use of a NFkB-GFP lentiviral Reporter in MDC iPSC Microglia **Demonstrates Response to Multiple Inflammatory Stimuli**







A) Schematic of NFKB-GFP lentiviral reporter. iPSC-derived microglia transduced with the reporter upregulate NFKB activity when exposed to various stimuli including LPS, β -amyloid and α - synuclein A53T. B) Live imaging of NFKB activity over 24hr shows upregulation within hours of stimulation **C)** Attenuation of activation by NFKB inhibitors 12 hr post stimulation





Signif DEGs

73

46

106





A) Schematic of ASC inflammasome reporter. ASC is fused to GFP in the and transduced iPSC-derived microglia. into Upon inflammasome activation with LPS/Nigericin, ASC changes localisation from diffuse in the cytoplasm to perinuclear specks (example images are shown). B) ASC speck count normalized to cell density, speck formation is prevented when treated with inflammasome inhibitor, mcc950. C) Caspase-1, activated downstream of ASC, is activated in response to inflammasome activation (luminescence reporter assay, Caspase Glo (Promega))



Innovate